35.28
前日終値:
$35.25
開ける:
$35.54
24時間の取引高:
4.01M
Relative Volume:
1.01
時価総額:
$15.25B
収益:
$2.31B
当期純損益:
$1.66B
株価収益率:
15.34
EPS:
2.3
ネットキャッシュフロー:
$827.02M
1週間 パフォーマンス:
-2.65%
1か月 パフォーマンス:
-1.95%
6か月 パフォーマンス:
+13.33%
1年 パフォーマンス:
+24.71%
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RPRX
Royalty Pharma Plc
|
35.28 | 15.24B | 2.31B | 1.66B | 827.02M | 2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-09-30 | 開始されました | Goldman | Buy |
2025-05-16 | 開始されました | Morgan Stanley | Overweight |
2024-06-03 | ダウングレード | UBS | Buy → Neutral |
2022-06-14 | 再開されました | UBS | Buy |
2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
2022-04-27 | 開始されました | Goldman | Buy |
2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
2022-04-06 | 再開されました | Morgan Stanley | Overweight |
2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
2021-07-30 | 開始されました | Tigress Financial | Buy |
2020-11-09 | アップグレード | UBS | Neutral → Buy |
2020-07-14 | 開始されました | Evercore ISI | In-line |
2020-07-13 | 開始されました | BofA Securities | Buy |
2020-07-13 | 開始されました | Citigroup | Neutral |
2020-07-13 | 開始されました | Cowen | Outperform |
2020-07-13 | 開始されました | Goldman | Neutral |
2020-07-13 | 開始されました | JP Morgan | Neutral |
2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
2020-07-13 | 開始されました | SunTrust | Buy |
2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma : Q3 2025 Pre-Quarterly Results Communication - MarketScreener
Goldman Sachs Initiates Coverage of Royalty Pharma (RPRX) with Buy Recommendation - Nasdaq
Royalty Pharma plc Stock Analysis and ForecastPrice Action Analysis & High Profit Investment Ideas - earlytimes.in
Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target - Investing.com UK
Goldman Sachs Starts Royalty Pharma (RPRX) at Buy, PT $42 - StreetInsider
Why Royalty Pharma plc stock is a must watch in 2025Market Growth Review & High Conviction Investment Ideas - newser.com
Royalty Pharma : Bernstein Healthcare Forum Transcript - MarketScreener
Royalty Pharma appoints Ted Love as lead independent director - Investing.com
Royalty Pharma names Dr. Ted Love as lead independent director - StreetInsider
Biotech Leader Ted Love Takes Key Board Role at Royalty Pharma, Bringing BIO Leadership Experience - Stock Titan
What candlestick patterns are forming on Royalty Pharma plcEarnings Trend Report & Stepwise Trade Execution Plans - newser.com
Will Royalty Pharma plc stock see PE expansion2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - newser.com
Overbrook Management Corp Trims Position in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock a smart buy before Fed meetingJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Understanding Royalty Pharma plc’s price movementGap Up & Breakout Confirmation Trade Signals - newser.com
Is Royalty Pharma plc RPD a good long term investmentStock Liquidity Analysis & Fast Growing Investment Plans - earlytimes.in
What analysts say about Royalty Pharma plc RPD stockDividend Reinvestment Plans & Free Tools to Monitor Market Corrections - Early Times
Why Royalty Pharma plc (RPD) stock could rally strongly2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
Assessing Royalty Pharma (RPRX): Is the Recent Outperformance Reflected in Its Current Valuation? - Yahoo Finance
Bank Pictet & Cie Europe AG Cuts Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - 富途牛牛
Ruffer LLP Makes New $6.41 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth - Insider Monkey
Wedge Capital Management L L P NC Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma at Bernstein Forum: Strategic Insights on Growth - Investing.com South Africa
Royalty Pharma at Bernstein Forum: Strategic Insights on Growth By Investing.com - Investing.com UK
Transcript : Royalty Pharma plc Presents at Bernstein Insights - MarketScreener
Mn Services Vermogensbeheer B.V. Acquires Shares of 67,000 Royalty Pharma PLC $RPRX - MarketBeat
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? - MSN
Royalty Pharma PLC $RPRX Shares Sold by Ridgewood Investments LLC - MarketBeat
Strs Ohio Invests $1.89 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum - The Manila Times
Pacific Capital Partners Ltd Sells 77,500 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Sell Signal: Does HAIN align with a passive investing strategyPortfolio Gains Report & Fast Momentum Entry Tips - khodrobank.com
Analyst Downgrade: Why is Royalty Pharma plc stock going downJuly 2025 Trends & AI Enhanced Trading Alerts - khodrobank.com
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today - Sahm
Leading Biopharma Royalty Investor Royalty Pharma Featured at Bernstein Healthcare Forum 2025 - Stock Titan
Layoff Watch: Will Royalty Pharma plc benefit from rate cutsWeekly Trend Recap & Stock Market Timing Techniques - khodrobank.com
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 226,048 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Market Outlook: Should I buy Royalty Pharma plc stock now2025 Market Overview & Daily Entry Point Alerts - خودرو بانک
Royalty Pharma (NASDAQ:RPRX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Nasdaq Moves: What are the analyst revisions for GCLWWIs Royalty Pharma plc stock a good investment in YEARJuly 2025 Macro Moves & Verified Chart Pattern Trade Signals - خودرو بانک
Royalty Pharma’s $2 Billion Debt Offering Could Be a Game Changer for RPRX - simplywall.st
TD Cowen Maintains a Buy on Royalty Pharma (RPRX) - Insider Monkey
Royalty Pharma Plc Experiences Evaluation Revision Amidst Market Dynamics and Performance Variability - Markets Mojo
Syndax, Royalty Pharma enter into $350M royalty funding deal - MSN
12 Affordable Biotech Stocks to Invest In Now - Insider Monkey
Empowered Funds LLC Buys New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Completes $2 Billion Senior Notes Offering - TipRanks
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):